Geron plunges as oncology lead imetelstat hits wall for solid tumours

Geron's stock price was cut in half on 10 September when the company said it would abandon development of its lead drug candidate in the treatment of solid tumours, because imetelstat failed in a Phase II clinical trial to improve progression-free survival (PFS) in patients with metastatic HER2-negative breast cancer.